These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 11535990

  • 1. Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
    García-Rayo S, Pérez-Calvo J, Martín-Algarra S, Martínez-Monge R, Fernández-Hidalgo O, Subirá L, Martínez-Aguillo M, Rebollo J, Azinovic I, Brugarolas A.
    Bone Marrow Transplant; 2001 Aug; 28(3):235-42. PubMed ID: 11535990
    [Abstract] [Full Text] [Related]

  • 2. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 3. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.
    Bone Marrow Transplant; 2001 Sep; 28(5):447-54. PubMed ID: 11593317
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2007 Dec 20; 25(36):5742-7. PubMed ID: 18089869
    [Abstract] [Full Text] [Related]

  • 5. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov 20; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 7. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW.
    Cancer; 2002 Sep 15; 95(6):1354-65. PubMed ID: 12216105
    [Abstract] [Full Text] [Related]

  • 8. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S, Feingold JM, Bona RD, Edwards RL, Khan AM, Rodriguez-Pinero F, Khan IA, Kazierad D, Clive J, Tutschka PJ.
    Bone Marrow Transplant; 2000 Jan 15; 25(2):123-30. PubMed ID: 10673668
    [Abstract] [Full Text] [Related]

  • 9. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
    Viens P, Palangié T, Janvier M, Fabbro M, Roché H, Delozier T, Labat JP, Linassier C, Audhuy B, Feuilhade F, Costa B, Delva R, Cure H, Rousseau F, Guillot A, Mousseau M, Ferrero JM, Bardou VJ, Jacquemier J, Pouillart P.
    Br J Cancer; 1999 Oct 15; 81(3):449-56. PubMed ID: 10507769
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS.
    Bone Marrow Transplant; 2002 Aug 15; 30(3):149-55. PubMed ID: 12189532
    [Abstract] [Full Text] [Related]

  • 12. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
    Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M.
    Br J Cancer; 2001 Nov 02; 85(9):1240-6. PubMed ID: 11720455
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
    Hohaus S, Wallwiener D, Martin S, Voso MT, Huober J, Fersis N, Bastert G, Haas R.
    Semin Oncol; 1998 Apr 02; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 02; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN.
    Cancer; 2006 Jun 01; 106(11):2327-36. PubMed ID: 16639731
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
    Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E.
    Biol Blood Marrow Transplant; 2002 Jun 01; 8(6):326-33. PubMed ID: 12108918
    [Abstract] [Full Text] [Related]

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A, Corringham S, Garrett J, Lane TA, Gilpin EA, Corringham RE, Law P, Ho AD.
    Bone Marrow Transplant; 2000 Mar 01; 25(5):519-24. PubMed ID: 10713629
    [Abstract] [Full Text] [Related]

  • 20. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL, Rey PM, Dansey RD, Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters WP, Baynes RD.
    Bone Marrow Transplant; 2000 May 01; 25(10):1047-52. PubMed ID: 10828864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.